Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
Wave Life Sciences (Nasdaq: WVE), a clinical-stage biotechnology company focusing on RNA medicines, has announced its participation in the Chardan 8th Annual Genetic Medicines Conference in New York City. Paul Bolno, MD, MBA, the company's President and CEO, is scheduled for an analyst-led fireside chat on Tuesday, October 1, 2024, at 1:00 p.m. ET.
The presentation will be accessible via a live webcast on the Investor Relations page of Wave Life Sciences' website. A replay will be available for a time after the event. This conference appearance underscores Wave Life Sciences' commitment to advancing RNA medicines and engaging with the investment community.
Wave Life Sciences (Nasdaq: WVE), una società di biotecnologie in fase clinica focalizzata sui farmaci a base di RNA, ha annunciato la sua partecipazione alla 8ª Conferenza Annuale sui Farmaci Genetici di Chardan a New York. Paul Bolno, MD, MBA, Presidente e CEO dell'azienda, è programmato per un incontro informale con gli analisti martedì 1 ottobre 2024 alle 13:00 ET.
La presentazione sarà accessibile tramite un webcast dal vivo sulla pagina delle Relazioni con gli Investitori del sito web di Wave Life Sciences. Una registrazione sarà disponibile per un certo periodo dopo l'evento. Questa partecipazione alla conferenza sottolinea l'impegno di Wave Life Sciences nell'avanzare i farmaci a base di RNA e nel coinvolgere la comunità degli investitori.
Wave Life Sciences (Nasdaq: WVE), una compañía de biotecnología en etapa clínica centrada en medicamentos de ARN, ha anunciado su participación en la 8ª Conferencia Anual de Medicamentos Genéticos de Chardan en Nueva York. Paul Bolno, MD, MBA, Presidente y CEO de la empresa, tiene programada una charla informal con analistas el martes 1 de octubre de 2024 a la 1:00 p.m. ET.
La presentación será accesible a través de un webcast en vivo en la página de Relaciones con Inversores del sitio web de Wave Life Sciences. Se dispondrá de una repetición por un tiempo después del evento. Esta aparición en la conferencia resalta el compromiso de Wave Life Sciences con el avance de los medicamentos de ARN y con el compromiso de la comunidad inversora.
웨이브 라이프 사이언스(Wave Life Sciences) (Nasdaq: WVE)은 RNA 의약품에 초점을 맞춘 임상 단계의 생명공학 회사로, 뉴욕에서 열리는 차던 제8회 유전자 의약품 회의에 참석할 예정입니다. 폴 볼노(Paul Bolno), MD, MBA가 2024년 10월 1일 화요일 오후 1시(ET)에 애널리스트와의 화상 채팅에 참여합니다.
프레젠테이션은 웨이브 라이프 사이언스 웹사이트의 투자자 관계 페이지를 통해 실시간 웹캐스트로 제공될 예정이며, 행사가 끝난 후 일정 기간 동안 다시 볼 수 있습니다. 이번 회의 참석은 RNA 의약품을 발전시키고 투자자 커뮤니티와 소통하려는 웨이브 라이프 사이언스의 의지를 강조합니다.
Wave Life Sciences (Nasdaq: WVE), une entreprise de biotechnologie en phase clinique se concentrant sur les médicaments à base d'ARN, a annoncé sa participation à la 8e Conférence Annuelle sur les Médicaments Génétiques de Chardan à New York. Paul Bolno, MD, MBA, le Président directeur général de l'entreprise, est prévu pour une discussion informelle avec les analystes le mardi 1er octobre 2024 à 13h00 ET.
La présentation sera accessible via un webinaire en direct sur la page des Relations Investisseurs du site Web de Wave Life Sciences. Une rediffusion sera disponible pendant un certain temps après l'événement. Cette participation à la conférence souligne l'engagement de Wave Life Sciences à faire avancer les médicaments à base d'ARN et à dialoguer avec la communauté des investisseurs.
Wave Life Sciences (Nasdaq: WVE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf RNA-Medikamente konzentriert, hat seine Teilnahme an der 8. jährlichen Konferenz zu genetischen Medikamenten von Chardan in New York City bekannt gegeben. Paul Bolno, MD, MBA, der Präsident und CEO des Unternehmens, wird am Dienstag, den 1. Oktober 2024, um 13:00 Uhr ET an einem Analystengespräch teilnehmen.
Die Präsentation wird über einen Live-Webcast auf der Investor-Relations-Seite der Webseite von Wave Life Sciences zugänglich sein. Eine Wiederholung wird nach der Veranstaltung eine Zeit lang verfügbar sein. Dieses Konferenzauftritt unterstreicht das Engagement von Wave Life Sciences, RNA-Medikamente voranzutreiben und mit der Investoren-Community in Kontakt zu treten.
- None.
- None.
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan 8th Annual Genetic Medicines Conference in New York City on Tuesday, October 1, 2024, at 1:00 p.m. ET.
A live webcast of this presentation will be available on the Investor Relations page of the Wave Life Sciences website at http://ir.wavelifesciences.com. A replay of this presentation will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.
Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com
Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com
FAQ
When is Wave Life Sciences (WVE) presenting at the Chardan Genetic Medicines Conference?
Who will be representing Wave Life Sciences (WVE) at the Chardan conference?
How can investors access Wave Life Sciences' (WVE) presentation at the Chardan conference?
What is the focus of Wave Life Sciences (WVE) as a company?
Will there be a replay available of Wave Life Sciences' (WVE) presentation at the Chardan conference?
